Phylloquinone is often called vitamin K1 or phytonadione. It is a fat-soluble vitamin that is stable to air and moisture but decomposes in sunlight. It is found naturally in a wide variety of green plants. Phylloquinone is also an antidote for coumatetralyl. Vitamin K is needed for the posttranslational modification of certain proteins, mostly required for blood coagulation. MEPHYTON (Phytonadione tablets) are indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. MEPHYTON tablets possess the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). The prothrombin test is sensitive to the levels of three of these four factors II, VII, and X. Vitamin K is an essential cofactor for the gamma-carboxylase enzymes, which catalyze the posttranslational gamma-carboxylation of glutamic acid residues in inactive hepatic precursors of coagulation factors II (prothrombin), VII, IX, and X. Gamma-carboxylation converts these inactive precursors into active coagulation factors, which are secreted by hepatocytes into the blood. Supplementing with Phylloquinone results in a relief of vitamin K deficiency symptoms, which include easy bruisability, epistaxis, gastrointestinal bleeding, menorrhagia and hematuria. Oral phytonadione is adequately absorbed from the gastrointestinal tract only if bile salts are present. After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues. Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine. In normal animals and humans, phytonadione is virtually devoid of pharmacodynamic activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function; that is, to promote the hepatic biosynthesis of vitamin K-dependent clotting factors. MEPHYTON tablets generally exert their effect within 6 to 10 hours.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P38435 Gene ID: 2677.0 Gene Symbol: GGCX Target Organism: Homo sapiens (Human) |
|||
Target ID: Q9BQB6 Gene ID: 79001.0 Gene Symbol: VKORC1 Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL2012 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16929463 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | VITAMIN K1 Approved UseVitamin K1 Injection is indicated in: (1) anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; (2) prophylaxis and therapy of hemorrhagic disease of the newborn; (3) hypoprothrombinemia due to antibacterial therapy; (3) hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; (4) other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. Launch Date1983 |
|||
Primary | VITAMIN K1 Approved UseVitamin K1 Injection is indicated in: (1) anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; (2) prophylaxis and therapy of hemorrhagic disease of the newborn; (3) hypoprothrombinemia due to antibacterial therapy; (3) hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; (4) other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. Launch Date1983 |
|||
Preventing | VITAMIN K1 Approved UseVitamin K1 Injection is indicated in: (1) anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; (2) prophylaxis and therapy of hemorrhagic disease of the newborn; (3) hypoprothrombinemia due to antibacterial therapy; (3) hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; (4) other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. Launch Date1983 |
|||
Secondary | MEPHYTON Approved UseMEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. MEPHYTON tablets are indicated in: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are
administered concurrently, since otherwise the oral vitamin K will not be absorbed. Launch Date1955 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28107923/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHYTONADIONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
146 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28107923/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHYTONADIONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28107923/ |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
PHYTONADIONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg 1 times / day steady, intravenous Highest studied dose Dose: 200 mg, 1 times / day Route: intravenous Route: steady Dose: 200 mg, 1 times / day Sources: |
unhealthy, 39 years |
|
1000 mg single, intravenous MTD Dose: 1000 mg Route: intravenous Route: single Dose: 1000 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: unknown Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Virucidal activity of retinal. | 1979 Sep |
|
Skin necrosis, a rare complication of coumarin therapy. | 1992 |
|
The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. | 1997 Nov 1 |
|
Interaction between fenofibrate and warfarin. | 1998 Jul-Aug |
|
Chemiluminescence analysis of menadione sodium bisulfite and analgin in pharmaceutical preparations and biological fluids. | 1999 Dec |
|
A conserved motif within the vitamin K-dependent carboxylase gene is widely distributed across animal phyla. | 2000 Nov 17 |
|
Hepatic failure and encephalopathy attributed to an interaction between acetaminophen and rifampicin. | 2001 Apr |
|
Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. | 2002 Aug |
|
[Molecular mechanisms of vitamin K action in the bone homeostasis]. | 2005 May |
|
Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. | 2006 Apr |
|
Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. | 2006 Jan |
|
Gradual improvement of liver function after administration of ursodeoxycholic acid in an infant with a novel ABCB11 gene mutation with phenotypic continuum between BRIC2 and PFIC2. | 2007 Nov |
|
CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. | 2009 Jun |
|
Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. | 2010 Jul |
|
Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. | 2010 Nov 4 |
|
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. | 2013 Sep 5 |
|
Vitamin K1 exerts antiproliferative effects and induces apoptosis in three differently graded human colon cancer cell lines. | 2015 |
|
Vitamin K1 distribution following intravenous vitamin K1-fat emulsion administration in rats. | 2015 Dec |
|
Vitamin K1 alleviates streptozotocin-induced type 1 diabetes by mitigating free radical stress, as well as inhibiting NF-κB activation and iNOS expression in rat pancreas. | 2015 Jan |
|
Effect of vitamin K supplementation on insulin sensitivity: a meta-analysis. | 2017 |
|
Phylloquinone (Vitamin K1): Occurrence, Biosynthesis and Functions. | 2017 |
|
Vitamin K plasma levels determination in human health. | 2017 May 1 |
|
Finding the optimal dose of vitamin K1 to treat vitamin K deficiency and to avoid anaphylactoid reactions. | 2017 Oct |
Sample Use Guides
Prophylaxis of Hemorrhagic Disease of the Newborn: A single intramuscular dose of (E)-phytonadione (Vitamin K1 Injection) 0.5 to 1 mg within one hour of birth is recommended. Treatment of Hemorrhagic Disease of the Newborn: 1 mg should be given either subcutaneously or intramuscularly. Anticoagulant-Induced Prothrombin Deficiency in Adults: the dose of 2.5 mg to 10 mg or up to 25 mg is recommended. Hypoprothrombinemia due to other causes: a dosage of 2.5 to 25 mg or more (rarely up to 50 mg) is recommended.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3684371
Curator's Comment: Vitamin K1 (VK1) inhibited the expression of heat-shock protein 72 (Hsp72) but did not affect the constitutive expression of Hsc70 or calnexin in vitro and in vivo. VK1 and VK2 sensitized A549 cells to heat-shock induced cell death, while the compounds alone had no effect on cell viability. The suppression of Hsp72 was apparently at the protein level because the mRNA expression of Hsp72 was unchanged.
Human lymphocytes were incubated with (E)-phytonadione at a dose of 1 uM. At this concentration (E)-phytonadione significantly increased Sister Chromatid Exchange.
Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 17:51:46 GMT 2025
by
admin
on
Mon Mar 31 17:51:46 GMT 2025
|
Record UNII |
A034SE7857
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175965
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NDF-RT |
N0000006290
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NDF-RT |
N0000006290
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
DSLD |
2725 (Number of products:1171)
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
WHO-ATC |
B02BA01
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
LOINC |
58793-1
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NDF-RT |
N0000006290
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NDF-RT |
N0000175982
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NCI_THESAURUS |
C943
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NDF-RT |
N0000006290
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NDF-RT |
N0000175965
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
LOINC |
9622-2
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
DSLD |
2515 (Number of products:1261)
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
WHO-VATC |
QB02BA01
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
LIVERTOX |
NBK548213
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NDF-RT |
N0000180191
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
10.2
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
NDF-RT |
N0000175966
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
||
|
DSLD |
208 (Number of products:446)
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
A034SE7857
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
28384
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
D014812
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
18067
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
DB01022
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201519
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
2843
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
D010837
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
Vitamin K
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
SUB16472MIG
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
8308
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
ALTERNATIVE | |||
|
177
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
SUB09800MIG
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
CHEMBL1550
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
C29365
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
100000091922
Created by
admin on Mon Mar 31 17:51:47 GMT 2025 , Edited by admin on Mon Mar 31 17:51:47 GMT 2025
|
PRIMARY | |||
|
1538006
Created by
admin on Mon Mar 31 17:51:47 GMT 2025 , Edited by admin on Mon Mar 31 17:51:47 GMT 2025
|
PRIMARY | |||
|
11258
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY | |||
|
A034SE7857
Created by
admin on Mon Mar 31 17:51:47 GMT 2025 , Edited by admin on Mon Mar 31 17:51:47 GMT 2025
|
PRIMARY | |||
|
PHYLLOQUINONE
Created by
admin on Mon Mar 31 17:51:46 GMT 2025 , Edited by admin on Mon Mar 31 17:51:46 GMT 2025
|
PRIMARY |
All of the following components must be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |